PT  - JOURNAL ARTICLE
AU  - Liao, Xiaoling
AU  - Feng, Shuo
AU  - Wang, Yicong
AU  - Pan, Yuesong
AU  - Chen, Weiqi
AU  - Qu, Hui
AU  - Zhao, Xingquan
AU  - Liu, Liping
AU  - Wang, Yongjun
AU  - Wang, Yilong
TI  - Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY): protocol for a multicentre, randomised controlled trial
AID  - 10.1136/svn-2022-002284
DP  - 2024 Feb 01
TA  - Stroke and Vascular Neurology
PG  - 75--81
VI  - 9
IP  - 1
4099  - http://svn.bmj.com/content/9/1/75.short
4100  - http://svn.bmj.com/content/9/1/75.full
SO  - Stroke Vasc Neurol2024 Feb 01; 9
AB  - Background Perforating artery territorial infarction (PAI) caused by branch atheromatous disease (BAD) is prone to recurrence and early progression without an effective and well-documented antiplatelet treatment regimen. Tirofiban, an adjunctive antiplatelet agent, has shown great potential to treat acute ischaemic stroke. However, whether the combination of tirofiban and aspirin can improve the prognosis of PAI remains unclear.Aim To explore an effective and safe antiplatelet regimen for reducing the risk of recurrence and early neurological deterioration (END) in PAI caused by BAD by comparing the tirofiban and aspirin combination with placebo and aspirin combination.Methods Tirofiban combined with Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction (STRATEGY) trial is an ongoing multicentre, randomised, placebo-controlled trial in China. Eligible patients shall be randomly assigned to receive standard aspirin with tirofiban or placebo on the first day and standard aspirin from days 2 to 90. The primary endpoint is a new stroke or END within 90 days. The primary safety endpoint is severe or moderate bleeding within 90 days.Discussion The STRATEGY trial will assess whether tirofiban combined with aspirin is effective and safe in preventing recurrence and END in patients with PAI.Trial registration number NCT05310968.Data sharing not applicable as no datasets generated and/or analysed for this study.